Cigna Announces CEO Succession: Brian Evanko to Take Helm as David Cordani Retires
This story was originally published on Healthcare Dive. To receive daily news and insights, subscribe to our free daily Healthcare Dive newsletter.
BLOMFIELD, Conn. – Cigna Group announced a planned leadership transition on Monday, with Chief Operating Officer Brian Evanko slated to succeed David Cordani as CEO upon Cordani's retirement in July. Cordani, who has led the health insurance conglomerate for nearly 17 years, will step down after a 33-year career with the company.
Evanko, a Cigna veteran of nearly three decades, was appointed COO last year in a broader executive reshuffle that placed both Cigna's insurance division and its Evernorth health services unit – home to pharmacy benefit manager (PBM) Express Scripts – under his oversight. He previously served as CFO and as CEO of the insurance division.
The CEO handoff arrives at a pivotal moment for Cigna. The company is managing the aftermath of a landmark settlement between its Express Scripts unit and the Federal Trade Commission, announced last month. The agreement resolved allegations that Express Scripts, along with rivals Optum Rx and CVS Caremark, conspired to inflate insulin prices.
While the settlement required Express Scripts to decouple its compensation from drugmaker rebates – a significant shift in PBM pricing models – Cigna leadership has downplayed the financial impact. On a recent investor call, Evanko asserted the company expects "comparable profitability" under the new model, with Express Scripts' earnings continuing to offset softer margins in the core insurance business.
"The source of profit will evolve, but the level is sustainable," Evanko told analysts. Company executives noted the settlement carried no financial penalty and that Express Scripts was already migrating employer clients to a revised benefits framework.
Industry Voices React
Michael Torres, Healthcare Analyst at Finley Advisory: "This is a textbook succession plan. Evanko's deep operational experience, especially his recent integration of the PBM and insurance units, positions him well to steer Cigna through an era of increased regulatory scrutiny on pharmacy pricing."
Dr. Anya Sharma, Physician and Patient Advocate: "A change at the top is meaningless if the business model remains the same. Cigna's PBM just settled over insulin price-fixing, and now the COO who oversaw that unit becomes CEO. This looks more like continuity of a problematic system than real change for patients struggling with drug costs."
Richard Greene, Former Insurance Executive: "Cordani's tenure saw massive growth and the transformative Express Scripts acquisition. Evanko's challenge is to defend those profits under a new regulatory reality. His internal credibility and financial acumen make him the safe choice for the board."
Lisa Chen, Portfolio Manager at Horizon Funds: "The market hates uncertainty, and this transition is remarkably smooth. Evanko's reassurance on PBM profitability post-settlement is crucial. It signals stability and that Cigna's integrated model can adapt to new rules."
Recommended Reading